<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230824059245N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-08-04</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of CO2 laser and scalpel surgery on scar quality in upper eyelid blepharoplasty</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Incision Site Scarring in Upper Eyelid Blepharoplasty Using CO2 Laser Versus Cold Steel Scalpel: A Non-Randomized Pilot Clinical Trial Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/91339</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: Because of the nature of the surgical intervention, blinding of the surgeon and participants is not feasible. Therefore, the study is designed as a single-blind clinical trial. To implement blinding, standardized photographs will be obtained from all participants before surgery and at the 60-day follow-up under identical conditions (camera angle, distance, lighting, and patient position). All photographs will be coded with unique identification numbers, and no information regarding the intervention (CO₂ laser or cold steel scalpel) will be available to the outcome assessors. Scar quality will be evaluated using the Manchester Scar Scale by three independent assessors who are not involved in the surgical procedures or patient allocation and are fully blinded to the intervention received. In addition, the statistical analyst will receive a coded dataset (e.g., Group A and Group B) without access to treatment allocation, and statistical analyses will be performed while remaining blinded to the intervention groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Upper Eyelid Blepharoplasty.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Upper eyelid blepharoplasty is performed using a CO₂ laser (Edge One, Jeisys, South Korea). An antibiotic-ointment-soaked eye shield is used for ocular protection. Laser settings include Continuous Wave mode, 100f tip, and 1 W power for the initial incision, and 3 W power for tissue excision. Local anesthesia is administered using 2% lidocaine with epinephrine (1:100,000), and the wound is closed with 6-0 nylon simple interrupted sutures. Intervention 2: Control group: Upper eyelid blepharoplasty is performed using a No. 15 surgical scalpel. Hemostasis is achieved using an electrocautery device in coagulation mode. Local anesthesia is administered using 2% lidocaine with epinephrine (1:100,000), and the wound is closed with 6-0 nylon simple interrupted sutures.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Still undecided - no release schedule yet</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nader Pazyar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital., 24 Meters., Azadegan St</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673166</zip>
        <telephone>+98 918 861 7133</telephone>
        <email>pazyar-n@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nader Pazyar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Khomeini Hospital., 24 Meters., Azadegan St</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6193673166</zip>
        <telephone>+98 918 861 7133</telephone>
        <email>pazyar-n@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being a candidate for blepharoplasty according to the dermatologist's opinion and not having any eye problems that would prevent the surgery
Age range between 30 and 60 years</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Refusal to participate in the study
Refusal to undergo blepharoplasty
Refusal to undergo CO₂ laser blepharoplasty
Coagulation disorders
Current use of anticoagulant medications
Abnormal coagulation test results (PT, PTT, INR, BT, or CT)
Previous eyelid surgery
History of eyelid trauma
Active skin disease of the eyelid
Active eyelid infection
Immunodeficiency disorders
Human immunodeficiency virus (HIV) infection
Hepatitis B infection
Hepatitis C infection
Diabetes mellitus with neuropathy
History of keloid formation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H02.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Ptosis of eyelid</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Upper eyelid blepharoplasty is performed using a CO₂ laser (Edge One, Jeisys, South Korea). An antibiotic-ointment-soaked eye shield is used for ocular protection. Laser settings include Continuous Wave mode, 100f tip, and 1 W power for the initial incision, and 3 W power for tissue excision. Local anesthesia is administered using 2% lidocaine with epinephrine (1:100,000), and the wound is closed with 6-0 nylon simple interrupted sutures.</i_keyword>
      <i_keyword>Control group: Upper eyelid blepharoplasty is performed using a No. 15 surgical scalpel. Hemostasis is achieved using an electrocautery device in coagulation mode. Local anesthesia is administered using 2% lidocaine with epinephrine (1:100,000), and the wound is closed with 6-0 nylon simple interrupted sutures.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Manchester Scar Scale score. Timepoint: Day 60 after surgery. Method of measurement: Scar score will be assessed on postoperative day 60 by three blinded assessors using the Manchester Scar Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-06-27</approval_date>
        <contact_name>Ethics Committee of Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>Jundishapur University of Medical Sciences، Koi Golestan، Ahvaz Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
